Tiger Brokers

Sino Biopharmaceutical FY2025 profit attributable to owners of the parent from continuing operations rises 22% to RMB2.34 billion; revenue grows 10.3% to RMB31.83 billion

Reuters
Mar 26
<a href="https://laohu8.com/S/SBHMY">Sino Biopharmaceutical</a> FY2025 profit attributable to owners of the parent from continuing operations rises 22% to RMB2.34 billion; revenue grows 10.3% to RMB31.83 billion
  • Sino Biopharm published an annual results announcement for the year ended Dec. 31, 2025, reporting revenue of RMB31.83 billion, up 10.3%.
  • Profit attributable to owners of the parent from continuing operations was RMB2.34 billion, up 22.0%.
  • Underlying profit attributable to owners of the parent was RMB4.54 billion, up 31.4%, mainly driven by revenue growth and a significant increase in dividend income.
  • Sales of innovative products were RMB15.22 billion, up 26.2%, lifting their revenue share to 47.8% from 41.8%.
  • The board recommended a final dividend of HKD0.05 per share, bringing the total dividend for the year to HKD0.10 per share.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sino Biopharmaceutical Limited published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260326-12068634), on March 26, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10